CTIX has a high probability of coming in this next year.

New Post Public Reply Private Reply Replies (3) Message Board
KarinCA

CTIX has a high probability of coming in this next year. May even get a pr that moves us first part of December.

The FDA protocols can almost be used as a calender. As specific points in the trial are hit the company will have data to pr. That's where first part of December comes in.

It's only a dollar at last close. Following are links of interest. Do your own DD. I'm just helping you get started.

CTIX articles:


Cellceutix CEO Leo Ehrlich Interviewed by TheStreetBeat.com
Leo Interview April 2012
http://www.zimbio.com/Dana-Farber+Cancer+Inst...StreetBeat

~~~~~~~~~~

analyst view
MAY 4, 2011

http://www.thegreenbaron.com/Cellceutix%20Ana...Format.pdf

or https://docs.google.com/viewer?a=v&q=cach...cWwqfyGefQ


~~~~~~~~~~


Pfizer Eyes Kevetrin?
August 13, 2012

http://seekingalpha.com/article/802771-pfizer-eyes-kevetrin

~~~~~~~~~~


Rodman and Renshaw part 1 and 2
September 11, 2012
http://cellceutix.com/events/

~~~~~~~~~~


Cellceutix Clinical Trials at Dana Farber and Beth Israel Deaconess Now Active
October 22, 2012
http://www.zimbio.com/Dana-Farber+Cancer+Inst...arber+Beth


~~~~~~~~~~


My Stock of the Year for 2013: Cellceutix Corporation (CTIX)
November 8, 2012 PUBLISHED IN: Market Analysis
http://www.allantrends.com/my-stock-of-the-ye...tion-ctix/

~~~~~~~~~~


BioTuesdays Says Cellceutix Better than Competition
November 22, 2012
http://www.zimbio.com/Blogger+Tips+and+Tricks...ompetition


General overview of dd
November 24, 2012
http://investorshangout.com/post/view?id=168277


~~~~~~~~~~

Kevetrin™ targets both MDM2-p53 and Rb-E2F pathways in tumor suppression
http://cellceutix.com/wp-content/uploads/pdfs...0FINAL.pdf

~~~~~~~~~~


FDA site listing protocols:

http://www.clinicaltrials.gov/ct2/show/NCT016...amp;rank=1

Phase one data points simplified: http://investorshangout.com/post/view?id=163713

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Ipsen's Kayfanda® Receives EU Approval for Alagille Syndrome Treatment

Updated Category News Views 67

Kayfanda® Receives Approval for Treatment in the EU Ipsen has made a noteworthy advancement in pediatric healthcare with the recent authorization of Kayfanda® (odevixibat) in the European Union (EU). This innovative treatment specifically addresses cholestatic pruritus, a painful symptom linked to Alagille Syndrome, a rare liver disorder that affects children. This...

Continue Reading
Discover the Remarkable Returns of Vulcan Materials Stock

Updated Category News Views 144

Unveiling Vulcan Materials Company Stock Performance Vulcan Materials Co. (NYSE: VMC) has been a noteworthy performer in the stock market over the past 15 years, surpassing market expectations with a commendable annual return of 15.1%. This stock has consistently outperformed the market, achieving an admirable 2.86% advantage annually. With a current market capitalization...

Continue Reading
AeroPress Launches Premium Coffee Press with Elegant Design

Updated Category News Views 332

AeroPress introduced its Premium coffee press back in 2024, and you can bet the market was watching closely. With a retail price of $149.95, this isn’t just another brewing tool; it’s a statement piece designed for those who take their morning ritual seriously. Traders buzzed about how this could impact sales in a saturated market where every new gadget fights for...

Continue Reading
Investigation Update: Walgreens Boots Alliance Class Action Lawsuit

Updated Category News Views 327

Overview of the Walgreens Boots Alliance Class Action Levi & Korsinsky, LLP has raised awareness among investors regarding a class action securities lawsuit involving Walgreens Boots Alliance, Inc. This company, known for its extensive pharmaceutical and retail operations, is currently facing legal challenges that could significantly impact its investors. Class Definition...

Continue Reading
Savillex Strengthens Market Position with New Acquisition

Updated Category News Views 38

Savillex Acquires Optimum Processing to Enhance Offerings Thompson Street Capital Partners (TSCP) is proud to announce that its portfolio company, Savillex, has completed the acquisition of Optimum Processing, Inc. This strategic move is expected to elevate Savillex's position in the marketplace by combining its innovative fluid handling solutions with Optimum...

Continue Reading